|
|
 Act sooner for at-risk patients
From early cues to coordinated follow-through across teams managing liver fibrosis
Your quick guide to early risk assessment and NIT use
|
|
MASLD and MASH* are evolving public health concerns. Our latest eBook, Unmasking a Silent Epidemic, summarizes current evidence, clarifies where noninvasive prognostic testing, such as the ELF® Test, fits within care pathways, and offers practical steps for earlier risk assessment. Written for laboratory and clinical leaders overseeing testing, quality, and integration across core, reference, and pathology services, this resource supports proactive and coordinated liver disease management.
This eBook highlights three key elements that provide valuable insight into:
- The epidemiology and clinical impact of MASLD and MASH
- Current techniques for effective patient management
- Growing trends of noninvasive testing and evidence-based outcomes
Staying current matters in healthcare. Review the full eBook to gain an edge.
|
|
| *Formerly known as nonalcoholic fatty liver disease (NAFLD) and nonalcoholic steatohepatitis (NASH). |
|
|
|
 
|
|
|
| About this email: SmartBrief will occasionally send emails from our business partners promoting products and services likely to
be of interest to our readers. The content of these messages does not necessarily reflect
the view of SmartBrief or its association partners. |
|
|
|
|
| Copyright © 2025 SmartBrief. All Rights Reserved. A division of Future US LLC. |
| Full 7th Floor, 130 West 42nd Street, New York, NY, 10036. |
|
|
|
